ClinicalTrials.gg
CompletedNCT05010551Updated Apr 28, 2022

Translation and Validation of MPCOSQ in Urdu Language

An observational study in PCOS- Polycystic Ovary Syndrome, sponsored by Riphah International University. Completed at 2 sites in Pakistan. Open to female participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2022-04-28.

Sponsored by Riphah International University · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
180
Ages
18 Years to 30 Years
Sex
Female
01

Study summary

To translate and validate modifies polycystic ovary syndrome quality of life (MPCOQ) questionnaire into Urdu. To evaluate the reliability, validity and of Urdu version of modified polycystic ovary syndrome quality of life questionnaire (MPCOQ).

Read the detailed description
  • All statistical analyses will be conducted using the Statistical Product and Service Solution version 21 software.
  • Continuous variables will be shown by mean and standard deviation and the categories will be demonstrated in frequency and percentage.
  • In this study, factor structure of the (MPCOQ) will be analyzed using the principal component factor analysis with varimax rotation.
  • Intraclass Correlation Coefficient (ICC) (95% confidence interval) will be used for test-retest value and Cronbach's Alpha will be used for internal consistency analysis.
  • Measurement error will be determined by calculating the standard error of measurement (SEM) and the Smallest Detectable Change (SDC). Independent t-test will be used to determine the differences between groups
02

Conditions studied

  • PCOS- Polycystic Ovary Syndrome
03

In context

Polycystic Ovary Syndrome

975 studies on the registry are indexed under Polycystic Ovary Syndrome; 177 are open to participants now.

This study's enrollment of 180 is above the median of 106 across 229 observational studies indexed under Polycystic Ovary Syndrome.

Browse Polycystic Ovary Syndrome studies →

Lead sponsor

Riphah International University is the lead sponsor of 2,176 studies on the registry; 637 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients diagnosed with PCOS

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Age 18 - 30

      • Married
      • Female patients diagnosed with PCOS, having 2 of the following Rotterdam diagnostic criteria:

I. Polycystic ovaries visualized on ultrasound scan (presence of 12 follicles or more in one or both ovaries and/or increased ovarian volume >10ml II. Clinical signs of hyperandrogenism (the hirsutism score based on the Ferriman-Gallwey score >7 or obvious acne) III. Having an interval between menstrual periods >35 days and/or amenorrhea as the absence of vaginal bleeding for at least 6 months, i.e. 199 days Patients who are willing to participate

Exclusion criteria

Exclusion Criteria:

    • Non-adrenal hyperplasia, thyroid dysfunction, and hyperprolactinemia

      • Female undergoing Hormone Replacement Therapy
      • Female with malignancies
      • Any recent fractures, surgeries
      • Patient with nephrological and neurological conditions
      • Dementia or cognitive impairments
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
180 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Modified polycystic ovary syndrome quality of life questionnaire

    The tool is to measure health related quality of life of females suffering from PCOS. it contains 30 items with 6 main areas related to hirsutism , acne, weight, infertility, emotional disturbance, menstrual difficulties to define different symptoms of PCOS. then quality of life will be measured of respective patients. The total is 210 with higher score indicating a better quality of life.

    Time frame: 6 months

07

Study locations

2 sites
  • Abeer Fatima
    Islamabad, Punjab Province 45000, Pakistan
  • Zohra Institute of Health Sciences
    Rawalpindi, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05010551
Responsible party
Sponsor
First posted
Aug 18, 2021
Start date
Nov 20, 2020
Primary completion
May 30, 2021
Completion
Aug 30, 2021
Last update
Apr 28, 2022

Study contacts

Sarah Ehsan
principal investigator · Riphah International University
Abeer Fatima, MS(cppt)
principal investigator · Riphah International University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion